Cargando…

Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity

[Image: see text] Codelivery of chemotherapeutic drugs in nanoparticles can enhance the therapeutic effects against tumors. However, their anticancer properties and physiochemical characteristics can be severely influenced by many formulation parameters during the preparation process. It is a compli...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Haiyang, Liao, Zuyue, Xu, Mengyao, Wan, Shengli, Wu, Yuesong, Zou, Wenjun, Wu, Jianming, Fan, Qingze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835547/
https://www.ncbi.nlm.nih.gov/pubmed/36643566
http://dx.doi.org/10.1021/acsomega.2c06359
_version_ 1784868690305482752
author Hu, Haiyang
Liao, Zuyue
Xu, Mengyao
Wan, Shengli
Wu, Yuesong
Zou, Wenjun
Wu, Jianming
Fan, Qingze
author_facet Hu, Haiyang
Liao, Zuyue
Xu, Mengyao
Wan, Shengli
Wu, Yuesong
Zou, Wenjun
Wu, Jianming
Fan, Qingze
author_sort Hu, Haiyang
collection PubMed
description [Image: see text] Codelivery of chemotherapeutic drugs in nanoparticles can enhance the therapeutic effects against tumors. However, their anticancer properties and physiochemical characteristics can be severely influenced by many formulation parameters during the preparation process. It is a complicated development phase to select the optimal parameters for preparation of nanoparticles based on the commonly used one single parameter method, which consumes a lot of money, time, and effort, and sometimes even fails. Therefore, the statistical analysis based on Box–Behnken design (BBD) has attracted much attention in bioengineering fields because it can illustrate the influence of parameters, build mathematical models, and predict the optimal combinational factors in a decreased number of experiments. In this study, we used a three-factor three-level BBD design to optimize the preparation of poly(lactic-co-glycolic acid) (PLGA) nanoparticles coloaded with two anticancer drugs curcumin and paclitaxel (PLGA-CUR-PTX nanoparticles). The surfactant concentration, polymer concentration, and oil–water ratio were selected as independent variables. An optimized model of the formulation for PLGA-CUR-PTX nanoparticles was validated. The optimal nanoparticles possessed a uniform spherical shape, with an average size of 99.94 nm, and the drug encapsulation efficiencies of CUR and PTX were 63.53 and 80.64%, respectively. The drug release from nanoparticles showed a biphasic release behavior, with a release mechanism via diffusion and fundamentally quasi-Fickian diffusion. The optimized nanoparticles demonstrated an enhanced cytotoxicity effect with lower IC(50) values to 4T1 and MCF-7 breast cancer cell lines compared to free drugs. In summary, BBD optimization of CUR and PTX coloaded nanoparticles yielded a favorable drug carrier that holds potential as an alternative treatment for anticancer therapy.
format Online
Article
Text
id pubmed-9835547
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-98355472023-01-13 Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity Hu, Haiyang Liao, Zuyue Xu, Mengyao Wan, Shengli Wu, Yuesong Zou, Wenjun Wu, Jianming Fan, Qingze ACS Omega [Image: see text] Codelivery of chemotherapeutic drugs in nanoparticles can enhance the therapeutic effects against tumors. However, their anticancer properties and physiochemical characteristics can be severely influenced by many formulation parameters during the preparation process. It is a complicated development phase to select the optimal parameters for preparation of nanoparticles based on the commonly used one single parameter method, which consumes a lot of money, time, and effort, and sometimes even fails. Therefore, the statistical analysis based on Box–Behnken design (BBD) has attracted much attention in bioengineering fields because it can illustrate the influence of parameters, build mathematical models, and predict the optimal combinational factors in a decreased number of experiments. In this study, we used a three-factor three-level BBD design to optimize the preparation of poly(lactic-co-glycolic acid) (PLGA) nanoparticles coloaded with two anticancer drugs curcumin and paclitaxel (PLGA-CUR-PTX nanoparticles). The surfactant concentration, polymer concentration, and oil–water ratio were selected as independent variables. An optimized model of the formulation for PLGA-CUR-PTX nanoparticles was validated. The optimal nanoparticles possessed a uniform spherical shape, with an average size of 99.94 nm, and the drug encapsulation efficiencies of CUR and PTX were 63.53 and 80.64%, respectively. The drug release from nanoparticles showed a biphasic release behavior, with a release mechanism via diffusion and fundamentally quasi-Fickian diffusion. The optimized nanoparticles demonstrated an enhanced cytotoxicity effect with lower IC(50) values to 4T1 and MCF-7 breast cancer cell lines compared to free drugs. In summary, BBD optimization of CUR and PTX coloaded nanoparticles yielded a favorable drug carrier that holds potential as an alternative treatment for anticancer therapy. American Chemical Society 2022-12-28 /pmc/articles/PMC9835547/ /pubmed/36643566 http://dx.doi.org/10.1021/acsomega.2c06359 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Hu, Haiyang
Liao, Zuyue
Xu, Mengyao
Wan, Shengli
Wu, Yuesong
Zou, Wenjun
Wu, Jianming
Fan, Qingze
Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity
title Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity
title_full Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity
title_fullStr Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity
title_full_unstemmed Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity
title_short Fabrication, Optimization, and Evaluation of Paclitaxel and Curcumin Coloaded PLGA Nanoparticles for Improved Antitumor Activity
title_sort fabrication, optimization, and evaluation of paclitaxel and curcumin coloaded plga nanoparticles for improved antitumor activity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835547/
https://www.ncbi.nlm.nih.gov/pubmed/36643566
http://dx.doi.org/10.1021/acsomega.2c06359
work_keys_str_mv AT huhaiyang fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity
AT liaozuyue fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity
AT xumengyao fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity
AT wanshengli fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity
AT wuyuesong fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity
AT zouwenjun fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity
AT wujianming fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity
AT fanqingze fabricationoptimizationandevaluationofpaclitaxelandcurcumincoloadedplgananoparticlesforimprovedantitumoractivity